After William Blair and BTIG gave Cellectis SA (NASDAQ: CLLS) a Buy rating last month, the company received another Buy, this time from JonesTrading. Analyst Soumit Roy initiated coverage with a Buy rating on Cellectis SA today. The company’s shares closed last Monday at $15.71.
According to TipRanks.com, Roy is a 5-star analyst with an average return of 19.4% and a 38.9% success rate. Roy covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Monopar Therapeutics Inc, and Aeglea Biotherapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cellectis SA with a $56.00 average price target, representing a 266.7% upside. In a report issued on February 19, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $20.84 and a one-year low of $9.50. Currently, Cellectis SA has an average volume of 131.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants.
Read More on CLLS:
